BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

As gene editing starts to make headway, its first indications are informed by the path laid by gene therapies and other nucleic acid modalities. But drug developers think editing is poised to move far beyond...
BioCentury | Sep 29, 2017
Financial News

Eligo raises $20M series A

On Sept. 26, microbiome company Eligo Bioscience S.A.S. (Paris, France) said it raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. CEO and Chairman...
BioCentury | Sep 27, 2017
Emerging Company Profile

Sparing the microbiome

Eliminating disease-causing bacteria from the gut while sparing healthy commensal bacteria is one of the key challenges of creating microbiome-based therapies. Eligo Bioscience S.A.S. has a platform that couples the editing power of CRISPR with...
BioCentury | Sep 26, 2017
Financial News

Eligo raises $20M series A

Microbiome company Eligo Bioscience S.A.S. (Paris, France) raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. The round included a $2 million award from...
BioCentury | Aug 31, 2017
Product R&D

Cutting through resistance

Most companies employing CRISPR- Cas9 for therapeutics are using it to edit human cells, but Locus Biosciences Inc. is betting the lesser-known CRISPR- Cas3 system will do a better job of treating bacterial infections and...
BioCentury | Nov 5, 2016
Finance

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...
BioCentury | Dec 21, 2015
Financial News

Seventure Partners financial update

Seventure Partners , Paris, France Business: Finance Date announced: 2015-12-14 Note: Seventure closed its Health for Life Capital Fund at EUR160 million ($175.3 million), exceeding its initial target of EUR120 million ($131.4million). New investor Novartis AG...
Items per page:
1 - 10 of 14
BioCentury | May 16, 2019
Emerging Company Profile

SNIPR: Turning CRISPR into a microbiome suicide

SNIPR is using CRISPR to target specific bacteria to fight infection or modulate the immune system. Growing interest in CRISPR for mammalian cells and microbiome-focused therapeutics led the company's co-founders, Christian Grøndahl, Morten Sommer and...
BioCentury | Mar 15, 2019
Finance

SNIPR targets the microbiome

SNIPR's strong IP position in prokaryotic CRISPR drew investors to a $50 million venture round led by Lundbeckfonden Emerge and LSP, the biggest series A yet for a CRISPR antibiotics and autoimmune company. Lundbeckfonden Emerge's...
BioCentury | Mar 5, 2019
Financial News

First close for Seventure's new microbiome fund

Seventure Partners announced the first close of its second microbiome-focused health fund and is targeting a €200 million ($226.9 million) final raise. Seventure's Isabelle de Cremoux said the VC has raised more than half of...
BioCentury | Feb 2, 2018
Tools & Techniques

Cutting a new path

As gene editing starts to make headway, its first indications are informed by the path laid by gene therapies and other nucleic acid modalities. But drug developers think editing is poised to move far beyond...
BioCentury | Sep 29, 2017
Financial News

Eligo raises $20M series A

On Sept. 26, microbiome company Eligo Bioscience S.A.S. (Paris, France) said it raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. CEO and Chairman...
BioCentury | Sep 27, 2017
Emerging Company Profile

Sparing the microbiome

Eliminating disease-causing bacteria from the gut while sparing healthy commensal bacteria is one of the key challenges of creating microbiome-based therapies. Eligo Bioscience S.A.S. has a platform that couples the editing power of CRISPR with...
BioCentury | Sep 26, 2017
Financial News

Eligo raises $20M series A

Microbiome company Eligo Bioscience S.A.S. (Paris, France) raised $20 million in a series A round led by new investor Khosla Ventures. Existing investor Seventure Partners also participated. The round included a $2 million award from...
BioCentury | Aug 31, 2017
Product R&D

Cutting through resistance

Most companies employing CRISPR- Cas9 for therapeutics are using it to edit human cells, but Locus Biosciences Inc. is betting the lesser-known CRISPR- Cas3 system will do a better job of treating bacterial infections and...
BioCentury | Nov 5, 2016
Finance

Vive la biotech

The French biotech sector has historically lagged other European countries such as the U.K. and Germany in both financings and deals. But a fledgling group of public bellwethers and a crop of innovative private companies...
BioCentury | Dec 21, 2015
Financial News

Seventure Partners financial update

Seventure Partners , Paris, France Business: Finance Date announced: 2015-12-14 Note: Seventure closed its Health for Life Capital Fund at EUR160 million ($175.3 million), exceeding its initial target of EUR120 million ($131.4million). New investor Novartis AG...
Items per page:
1 - 10 of 14